Claims
- 1. A compound represented by the following structural formula:
- 2. The compound of claim 1, wherein R is —H.
- 3. The compound of claim 2, wherein:
the aryl rings are each optionally and independently substituted, and the alkylene spacer molecule is independently substituted with one or more groups selected from halogen, dimethylaminocarbonyl, fluoroalkyl, hydroxy, C1-6 alkyl, C1-6 alkoxy, carboxylic acid, methylhydroxy, methylcarbonyl, cyano, aminomethyl, (aminoalkyl), ethoxycarbonylmethoxy, cyanomethyloxy, (acetoxyethyl)oxy, (hydroxyoxyethyl)oxy, morphilinoethyloxy, (tetrazol-5-yl)methyloxy, carboxymethyloxy, dimethylaminocarbonylmethyloxy, morphilinocarbonylmethyloxy, (1-ethoxycarbonyl-1-methylethyl)oxy, (1-carboxy-1methylethyl)oxy, (2-methoxyethyl)oxy, (1-dimethylaminocarbonyl-1-methylethyl)oxy, (1-ethoxycarbonyl)cyclobutoxy, (1-carboxy)cyclobutoxy, (1,1-dimethyl-2-hydroxyethyl)oxy, (2,2-dimethyl-2-hydroxyethyl)oxy, acyloxy, cycloalkyl, arylalkyl, alkoxycarbonyl, and substituted or unsubstituted amines.
- 4. The compound of claim 2, wherein:
the aryl rings are optionally and independently substituted with one or more substituents selected from hydrogen, halogen, alkyl, fluoroalkyl, hydroxy, alkoxy, —(O)u—(CH2)t—C(O)OR4, —(O)u—(CH2)t—OC(O)R4, —(O)u—(CH2)t—C(O)—NR5R6 and —(O)u—(CH2)t—NHC(O)O—R4; wherein:
t is an integer from 0 to 3; —(CH2)t— is substituted or unsubstituted; and R4, R5, and R6 are independently hydrogen, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group, or R5 and R6, taken together with the nitrogen atom to which they are bonded, are a non-aromatic heterocyclic ring.
- 5. The compound of claim 2, wherein:
the aryl rings are optionally and independently substituted and the alkylene spacer molecule is independently substituted with one or more of halogen, —OH, —CO2H, alkylimine, alkylsulfonyl, carboxamido, carboxylic alkyl esters, —CH═NH, —NO2, azido, cyano, fluoroalkyl, —CONR8R9, —NR8R9, —OS(O)2NR8R9, —S(O)2NR8R9, sulfonic acid, sulfonamide, guanidino, —(O)u—(CH2)t—C(O)OR4, —(O)u—(CH2)t—OC(O)R4, —(O)u—(CH2)t—C(O)—NR5R6, —(O)u—(CH2)t—NHC(O)O—R4, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), -Q-(CH2)p-(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or -Q-(CH2)p-(non-aromatic heterocyclic group); wherein:
p is an integer from 1 to 5; u is 0 or 1; Q is —O—, —S—, —S(O)—, —S(O)2—, —OS(O)2—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)C(O)—O—, —O—C(O)C(O)—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—, —NH—C(O)—NH—, —S(O)2NH—, —NHS(O)2—, —N(R7)—, —C(NR7)NNNH—, —NHNHC(NR7)—, —NR8C(O)— or —NR8 S(O)2—; R4, R5, and R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, —NHC(O)—O-(aliphatic group), —NHC(O)—O-(aromatic group) or —NHC(O)—O-(non-aromatic heterocyclic group), or R5 and R6, taken together with the nitrogen atom to which they are bonded, are a non-aromatic heterocyclic ring; R7 is —H, an aliphatic group, a benzyl group, an aryl group or a non-aromatic heterocyclic group; and R8 and R9 are independently -H, hydroxy, an aliphatic group, a substituted aliphatic group, a benzyl group, an aryl group or a non-aromatic heterocyclic group.
- 6. The compound of claim 2, wherein the compound is represented by the following formula:
- 7. The compound of claim 6, wherein X1 is O.
- 8. The compound of claim 3, wherein the alkylene spacer is disubstituted.
- 9. The compound of claim 8, wherein the alkylene spacer is geminally dialkylated.
- 10. The compound of claim 9, wherein the alkylene spacer is geminally dimethylated.
- 11. The compound of claim 10, wherein the compound is selected from the group of compounds consisting of:
- 12. The compound of claim 11, wherein the alkylene spacer is singly substituted with a substituent other than a noncyclic alkyl group.
- 13. The compound of claim 12, wherein the alkylene spacer is substituted with a heteroatom or a cyclic substituent.
- 14. The compound of claim 13, wherein the cyclic substituent is a cycloalkyl group or a cyclic ether group.
- 15. The compound of claim 14, wherein one or more of the carbons of the alkylene spacer is contained in the cyclic substituent.
- 16. The compound of claim 15, wherein the compound is selected from the group of compounds consisting of:
- 17. The compound of claim 1, wherein the compound is represented by the following formula:
RELATED APPLICATIONS
[0001] This is a continuation of U.S. application Ser. No. 10/272,510, filed Oct. 16, 2002, which claims the benefit of U.S. Provisional Patent Application Serial No. 60/329,701, filed on Oct. 16, 2001, entitled “Treatment of CNS Disorders Using CNS Target Modulators”; pending U.S. Provisional Patent Application Serial No. 60/381,507, filed on May 17, 2002, entitled “Treatment of CNS Disorders Using CNS Target Modulators”; and pending U.S. Provisional Patent Application Serial No. 60/414,243, filed on Sep. 27, 2002, entitled “Treatment of CNS Disorders Using CNS Target Modulators”. This application is also related to pending U.S. Provisional Patent Application Serial No. 60/418,821 filed on Oct. 16, 2002, entitled “Treatment of CNS Disorders Using CNS Target Modulators”. The entire content of each of the above-identified applications is hereby incorporated herein by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60329701 |
Oct 2001 |
US |
|
60381507 |
May 2002 |
US |
|
60414243 |
Sep 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
| Parent |
10272510 |
Oct 2002 |
US |
| Child |
10728340 |
Dec 2003 |
US |
Patent Application
20040142972
